Presenter:Prof Spyridonidis Participants:Dr Liga, Dr Spyridis, Dr Lekka, Dr Katsaouni

We discussed a case of conjuctival MALT lymphoma and reviewed the  current literature.   Presenter:Prof.Spyridonidis Participants:Dr Liga, Dr Spyridis, Dr Lekka, Dr Katsaouni

Presenter:Prof. Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Lekka, Dr Katsaouni

Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Lekka, Dr Katsaouni

Presenter:Prof.Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Lekka, Dr Katsaouni

We discussed 2 interesting papers for mechanisms of relapse post allogeneic HSCT which can be either HLA-loss, HLA-down regulation or immune escape. Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Lekka, Dr Katsaouni

Presenter: Prof. Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Lekka, Dr Katsaouni

An update on CMV was presented. We discussed the open access slides of the ECIL 7 consensus on CMV. In addition we discussed the recently change of the LAb which performs CMV monitoring and the new reporting (from copies/ml to IU/ml). We discussed...

We discussed the REV infections in HSCT recipients. Presenter: Prof. Marangos Participants: Prof. Spyridonidis, Dr Liga, Dr Spyridis, Dr Lekka, Dr Katsaouni

We presented a study that showed that NGS-based MRD is widely  applicable to AML patients, is highly predictive of relapse and  survival, and may help refine transplantation and posttransplantation  management in AML patients. Presenter: Prof. Spyridondis Patricipants: Dr Liga, Dr Spyridis, Dr Lekka, Dr Bountouris

We presented Treatments that made headlines in hematology in 2018. From  Nature Medicine 24,1785–1787 (2018) Presenter: Prof. Spyridonidis Paricipants: Dr Liga, Dr Spyridis, Dr Lekka, Dr Bountouris   Green light CD19 CAR therapy Chimeric antigen receptor (CAR) therapy using the CD19 antigen continued to show its benefits after a long-term follow-up study found that...

Early-Stage Follicular Lymphoma: What Is the Preferred Treatment  Strategy  in Early-Stage Follicular Lymphoma? WW, RT, Chemo,  Immunoterpay or a combination of the above? Porobaly lla are the saem  iof one consideres OS as outocem,but may differ in regard to EFS.   A critical opinion on a randomized study...

A Japanese study questioned the "favorable" status of AML with low  allelic ratio FLT3-ITD and NPM1 mutation given by ELN criteria. Flt3 mut  presence is a clear indication for AML. Presenter:Prof. Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Lekka, Dr Bountouris

Which is the best conditioning in ALL? Slides that we presented in  EBMT ALWP in Krakow 2018. The slides present the current policy in Patras. Presenter: Prof.Spyridonidis Pariticpants: Dr Liga, Dr Spyridis, Dr Lekka, Dr Bountouris              

We review again the BK cystitis and our current SOPs. We discussed the  initiation of a prosepctive study with intravesicular cidofovir. Presenter: Prof. Spyridondis Participants: Dr Liga, Dr Spyridis, Dr Lekka, Dr Bountouris

Retrospective studies indicating that specific comorbidities are  associated with increased NRM in specific conditoning regimens. For  example cardiac disease is high toxic in BUFlu regimens. These results have been implemented in our daily clinical praxis. Presenter: Prof. Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Lekka, Dr Bountouris.    

We presented the Consensus of North American Experts regarding MRD in ALL Management and the algorithm for allo/HSCT. Presenter: Prof. Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Lekka, Dr Bountouris.

We discussed the results of a randomized study on Azacitidine with or  without eltrombopag for first-line treatment of intermediate- or  high-risk MDS with thrombocytopenia. The study was closed premature because of a negative effect of  eltromombag both on thrombocytopenia and time to progress to AML. Presenter: Prof. Spyridonidis Participants: Dr...